As the United States marks its 250th anniversary, it is worth stepping back from the daily information cycle to consider the environment surrounding American life science in a longer frame.
ExSight Ventures announced an investment in DefEYE, Inc. DefEYE uses decellularized placental-based tissue for ocular surface disease and ocular surgical management.
ExSight Ventures’ 2025 market outlook says early-stage life science innovation, especially in ophthalmology, offers long-term investment potential amid political disruption, trade tensions and regulatory upheaval.
ExSight Ventures announced an investment in RevOpsis Therapeutics, a biotechnology company developing therapies for retinal diseases. Its platform combines protein engineering with validated biological pathways to develop therapies intended to improve durability, efficacy and patient outcomes.
ExSight Venture Management, LLC states that its Terms of Use form a legally binding contract between users and ExSight Ventures, LLC regarding use of the site.